CXCL1 and infection: The combination treatment with both TMAO and CFT073 had significant additive effects on the release of CXCL11 and CCL20 and synergistic effects on the release of IL-8, CXCL1, and CXCL6 compared to CFT073 infection alone (Figure 1).